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Abstract
Grade II gliomas are slowly growing primary brain tumors that affect mostly
young patients and become fatal after a few years. Current clinical handling
includes surgery as first line treatment. Cytotoxic therapies (radiotherapy RT
or chemotherapy QT) are used initially only for patients having a bad progno-
sis. Therapies are administered following the ’maximum dose in minimum time’
principle, what is the same schedule used for high grade brain tumors. Using
mathematical models describing the growth of these tumors in response to radio-
therapy, we find that a extreme protraction therapeutical strategy, i.e. enlarging
substantially the time interval between RT fractions, may lead to a better tu-
mor control. Explicit formulas are found providing the optimal spacing between
doses in a very good agreement with the simulations of the full three-dimensional
mathematical model approximating the tumor spatio-temporal dynamics. This
idea, although breaking the well-stablished paradigm, has biological meaning
since in these slowly growing tumors it may be more favourable to treat the
tumor as the different tumor subpopulations move to more sensitive phases of
the cell cycle.
Keywords: Low-grade gliomas; Radiotherapy; mathematical models of tumor
growth
1. Introduction
Gliomas as a group are the most frequent type of primary brain tumors.
With few unfrequent exceptions aside, these tumors remain a challenge for
medicine since therapies cannot eradicate them due to their infiltrative nature.
Patients diagnosed with gliomas typically die because of the complications re-
lated to the tumor evolution.
Low grade glioma (LGG) is a term used to describe WHO grade II primary
brain tumors of astrocytic and/or oligodendroglial origin (Louis et al. 2007).
They represent a subgroup of gliomas with moderate incidence that are diag-
nosed mostly in young adults.
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These tumors have a slow growth but are highly infiltrative and generally
incurable, the median survival time being of about 5 years (Pignatti et al. 2002;
Pouratian & Schiff 2010). While some patients present with easy to control
seizures and remain stable for many years, others undergo soon the so called ma-
lignant transformation and progress rapidly, with increasing neurological symp-
toms, to a higher-grade tumor.
Management of LGG is controversial because many of these patients present
few, if any, neurological symptoms. Recent evidences support that the early use
of surgery results in a better outcome than the historically used watch and wait
approach (Grier and Batchelor 2006; Smith et al. 2008; Jakola et al. 2012).
The decision as to whether a patient with LGG should receive resection,
radiation therapy (RT), or chemotherapy is based on a number of factors in-
cluding age, performance status, location of tumor, and patient preference
(Ruiz & Lesser 2009; Pouratian & Schiff 2010). Since LGGs are such a hetero-
geneous group of tumors with variable natural histories, the risks and benefits
of each therapy must be carefully balanced with the data available.
As to RT, the clinical trial by Garcia et al (2004) showed the advantage
of using radiotherapy in addition to surgery. However, the timing of radio-
therapy after biopsy or debulking is debated (Chao and Suh 2006). It is now
well known that immediate radiotherapy after surgery increases the time of re-
sponse (progression-free survival), but does not seem to improve overall survival
(Van den Bent 2005). At the same time the therapy induces serious neurolog-
ical deficits as a result to normal brain damage. Thus, radiotherapy is usually
offered to patients with a combination of poor risk factors such as age, sub-
total resection, or diffuse astrocytoma pathology (Higuchi et al. 2004) or those
suspicious of having undergone the malignant transformation.
Mathematical modeling has the potential to help in selecting LGGs patients
that may benefit from radiotherapy and in developing specific optimal frac-
tionation schemes for selected patient subgroups. The increasing availability
of systematic and quantitative measurements of tumor growth rates provides
bench examples and typical features of the dynamics providing key informa-
tion for the development and validation of such models (see e.g. Pallud et al.
(2012,b) for LGGs).
Most of the mathematical research on gliomas has been focused on the
study of high-grade gliomas (Swanson et al 2003; Clatz 2005; Jbadi et al. 2005;
Stamatakos et al. 2006,b; Fedotov et al. 2011; Frieboes et al. 2007; Bondiau et al.
2008; Swanson et al. 2008; Wang et al. 2009; Tanaka et al. 2009; Eikenberry et al.
2009; Roniotis et al 2010; Lowengrub et al. 2010; Gu et al 2012; Swanson et al.
2011; Mart´ınez-Gonza´lez et al. 2012, 2014; Pe´rez-Garc´ıa et al 2014). Most of
these models add different layers of complexity on top of the basic Fisher-
Kolmogorov reaction diffusion equation (Murray 2007) to be described in detail
later. The role of radiotherapy has also been studied mostly o high-grade tumors
(Rockne et al. 2010; Bondiau et al. 2011; Konukoglu et al. 2010; Kirkby et al.
2010; Leder et al 2014). As to LGGs there have been very few relevant works
using mathematical models to describe the response to RT. Ribba et al (2012)
developed a model based on ordinary differential equations describing the re-
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sponse of low-grade glioma to different therapies with a number of undetermined
parameters that can be fit to describe the individual patient’s response with a
good qualitative agreement. More recently Pe´rez-Garc´ıa et al (2014) have de-
veloped a simple spatial model able to describe the known phenomenology of the
response of LGGs to RT including the observations from Pallud et al. (2012b).
Also Galochkina et al. (2014) have found that small variations of the standard
dose distributions and/or changes in the fractionation lead only to minor im-
provements at the best, in agreement with clinical experiences.
However it is not clear from the biological point of view that current schedul-
ing of radiotherapy is optimal considered from a more global point of view. The
fact that radiation doses are given in a very short period of time (i.e. one dose
per day during five weeks with breaks in the weekends) comes from the idea
of reducing the tumor load as much as possible in order to kill every clono-
genic cell without allowing the tumor to regrow between doses. While this is
a reasonable practice when radiation therapy is used with curative intentions,
it is not obvious that an incurable tumor such as a LGG should receive doses
in the same way. Indeed LGG grow very slowly, with a very low number of
mitoses seen per field what means that only a small fraction of tumor cells is
proliferating at a given time and is sensitive to radiation therapy. Thus, it may
be reasonable to enlarge the distance between fractions, i.e. to restort to a
protracted therapeutical scheme, to allow for more tumor cells to enter the cell
cycle rendering radiation fractions more effective. This idea opens the door to
substantially modified schedules that will be studied using mathematical models
in this paper.
Our plan in this paper is as follows. First in Sec. 2 we present the mathe-
matical models to be used through the paper. Next in Sec. 3 we find the optimal
therapeutical protocols and discuss the expected gain as a function of the pa-
rameters. Explicit formulas are found providing the spacing between doses as a
function of the biological parameters of the tumor in very good agreement with
the results of full three-dimensional simulations. Finally in Sec. 4 we discuss
the implications of our results and summarize our conclusions.
2. Mathematical model
To fix the mathematical model we have to describe what is: (i) the dy-
namics of the tumor, (ii) the response of the tumor to radiation, and (iii) the
optimization criterion to be used in designing the dose scheduling.
2.1. Tumor cell dynamics
For the tumor cell dynamics we will use the simplest model accounting for the
growth of a spatio-temporal density u(x, t) of tumor cells in units of a maximal
cell number that proliferate with a typical time 1/ρ and have a characteris-
tic mobility (diffusion) coefficient D, namely the Fisher-Kolmogorov equation
(Murray 2007)
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∂u
∂t
= D∆u + ρ(1− u)u, (1a)
on a domain Ω of the brain supplemented with initial data
u(x, t0) = u0(x), u0(x) ∈ C
2(Ω¯), (1b)
and no-flux boundary conditions
∂u
∂n¯
∣∣∣∣
∂Ω
= 0, (1c)
This model has been extensively used to describe the dynamics of low grade
gliomas (Gerin et al 2012; Alvord & Swanson 2007; Harpold et al 2007; Roniotis et al
2010). Let us note (see e.g. Pardo et al (2014)) that 0 ≤ u(x, t) ≤ U(t) where
U(t) is an upper bound for the tumor amplitude solving
dU
dt
= ρ(1− U)U, (2)
with U(0) = maxx∈Ω u(x, 0). In addition to providing an upper bound for the
tumor cell density, Eq. (2) has also been proven to provide the evolution of the
tumor amplitude A(t) = maxx∈Ω u(x, t) with good accuracy in one-dimensional
scenarios (Belmonte et al. 2014). Since we will be dealing with low grade gliomas
the focus of the therapy will be on limiting disease symptoms and delaying the
most its transformation into a higher-grade tumor. It has been discussed that
high density cell foci may lead to tumor transformation (Swanson et al. 2011;
Pe´rez-Garc´ıa et al 2014), thus, in this paper we will first focus on understanding
and controlling the dynamics of Eq. (2) in Secs. 3.1 to 3.4. Next, in Sec. 3.5
we will complete our study with a comparison of our findings with the results
for the full dynamics of Eq. (1) in three-dimensional scenarios.
2.2. Response to RT
Radiotherapy is given in a short time (typically about 10 minutes) in compar-
ison with typical cellular proliferation times in low-grade gliomas, what allows
us to assume the effect of RT to be instantaneous.
Following the standard practice in radiotherapy we will assume the damaged
fraction of tumor cells to be given by the classical linear-quadratic (LQ) model
(Van der Kogel & Joiner 2009). Thus for a radiation dose dj given at a time
tj , we will take the survival fraction Sj , i.e. the fraction of cells that are not
lethally damaged to be given by
Sj = e
−αtdj − βtd
2
j . (3)
The parameters αt and βt are respectively the linear and quadratic coefficients
for tumor cell damage of the LQ model.
The full treatment consists of a total dose D split in a series of N radi-
ation fractions with doses per fraction {dj}j=1,...,N given at irradiation times
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{tj}j=1,...,n. The tumor cell density of functionally alive tumor cells u(x, t) at
the irradiation times will then satisfy
u(x, t+j ) = Sju(x, t
−
j ), (4)
what reflects directly on a similar equation for the tumor amplitude U(t):
U(t+j ) = SjU(t
−
j ). (5)
2.3. Optimization problem
Damage to normal tissues caused by radiotherapy can be estimated using
Eq. (3) but taking instead the parameters of the normal tissue αh, βh with
αh/βh ≃ 2 (Wigg 2001). It is reasonable that any radiotherapy fractionation
should keep the damage to the normal tissue equal or below that of the standard
fractionation, what can be quantified, given a certain set of doses (tj , dj) as (see
e.g. Van der Kogel & Joiner (2009) pp. 114).
Eh = − log

 n∏
j=1
Sj

 = αh

D + 1
αh/βh
n∑
j=1
d2j

 . (6)
In addition, acute tissue reactions and other secondary effects depend: (i) on
the total volume irradiated (the so-called volume effect) and (ii) on the maximal
dose per fraction d∗ used. We will not be interested in this paper on spatial
aspects of radiation therapy or other complications (?) and thus will assume
that all tumor cells within the tumor receive the same ammount of radiation.
Mathematical optimization has the potential to help in finding optimal ther-
apeutic schedules, spatial dose distributions, etc. To do so once a particular tu-
mor evolution model has been chosen and paired with a model for the response
to radiation we must choose a cost functional related to the optimization objec-
tive.
In the case of high grade brain tumors, where there is no metastatic spreading
it has been hypothesized that death occurs in high grade tumors after the tumor
reaches a critical diameter of about 6-7 cm (Swanson et al. 2008; Wang et al.
2009). However, high grade gliomas are very aggressive tumors that due to the
formation of necrotic areas result is a complete loss of functionality in areas
affected by macroscopic tumor (Pe´rez-Garc´ıa et al. 2011).
In LGGs the situation is different. Because of the low density of the tumor
the tissue affected is still partially functional and the slow tumor growth allows
the brain to remap continuously the affected functionality into healthy brain
areas. The most harmful effect of the LGG is its potential to transform into a
high-grade tumor. So the optimal therapy would be the one delaying the most
the malignant transformation of the tumor while at the same time helping to
keep the disease symptoms under control.
One of the driving forces of the malignant transformation is an increase of
mutation rates originated by the changes in tumor microenvironment due to the
continuous density increase. These include vessel damage, generation of hypoxic
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foci, the stabilization of hypoxia dependent signaling molecules such as HIF-1α
and the increase of genomic instability (Mart´ınez-Gonza´lez et al. 2012; Semenza
2003; Poon et al 2009; Mart´ınez-Gonza´lez et al. 2014).
Thus, we will design the therapy to maintain the tumor density below a
critical level U∗ for the longest time possible, i.e., to make the time T such that
T : max
Ω
u(t, x) ≤ u∗ ≡ U(t) ≤ U∗ (7)
as large as possible. Maximizing T given by Eq. (7) under the constraints of
maximal dose allowed (dj ≤ d∗, k = 1, . . . , N) and iso-damage to the normal
tissue given by Eq. (6) is a mathematical optimization problem that can be
solved for the number of doses N , irradiation times {tj}
N
j=1 and doses {dj}
N
j=1.
In what follows we will refer to the time T given by Eq. (7) as the time to
malignant transformation (TMT).
In this paper we will not study the full optimization problem and our focus
will be on demonstrating a theoretical proof of concept of the extreme protaction
strategy for LGGs, thus grounding mathematically a radically different approach
to the planning of radiotherapy for LGGs. As such we will fix the number of
radiation doses and doses per fraction to be exactly those of the most extended
radiotherapy protocols for these tumors, i.e. take the number of fractions N =
30 and doses per fraction dj = 1.8 Gy, what keeps the value of the functional Eh
in Eq. (6) and satisfies the restriction that dj ≤ 3.2 Gy. Our only optimization
parameter will be then the time spacing between doses.
2.4. Parameter estimation
In the problem to be studied in this paper there remain few biological param-
eters describing at a macroscopic level the essentials of the LGG dynamics and
response to therapy. First, proliferation rates for LGGs have been estimated
to be around 0.003 day−1 in Gerin et al (2012) what gives doubling times of
the order of one year. From the most indolent tumors to those more aggressive
within the class of LGGs the full range may comprise an order of magnitude.
The surviving fraction Sf for doses of 1.8 Gy is harder to estimate. It is known
that gliomas are very radioresistant tumors with high surviving fractions in-
vitro and mixed response to radiation in-vivo. We will follow the approach
of Pe´rez-Garc´ıa et al (2014) that estimate this value from the radiological re-
sponse fitting the typically observed dynamics of the mean tumor diameter
(Pallud et al. 2012) what gives values in the range Sf ∼ 0.8− 0.9.
Finally, the tumor cell densities leading to relevant symptoms and disease de-
tection (U0) and the threshold density beyond which harmful symptoms appear
and/or promoting the malignant transformation (U∗), are difficult to estimate.
Normal brain tissue has low cellularity and the cell density leading to symptoms
is probably dependent on the location of origin of the tumor. However, most
LGGs are supratentorial and appear in the white matter. We will take the initial
density to be around U(0) = 0.3 what means that symptoms arise when 30% of
the space is occupied by tumor cells, a number well beyond the normal phys-
iological value that may be around 10-15%. As to the maximal tissue density
leading to irreversible damage, we will take it to be around U∗ = 0.5− 0.6.
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The biological and clinical parameters used through this paper are summa-
rized in Table 2.4.
Variable Description Value (Units) References
ρ Proliferation ∼ 0.003 day−1 Gerin et al (2012)
rates
d Dose per fraction 1.8 Gy Karim et al (1996)
N Number of doses 25-30 Soffietti et al. (2010)
SF1.8 Survival fraction ∼ 0.8-0.9 Pe´rez-Garc´ıa et al (2014)
U(0) Initial cell density 0.3 Estimated
U∗ Critical cell density 0.5-0.6 Estimated
Table 1: Values of the biological and clinical parameters used in the mathematical model of
LGG evolution.
3. Results
3.1. Equations for the amplitude evolution
Solving explicitly Eq. (2) and using the recursion formula (5) we get a
recursive equation providing the tumor amplitude after every dose tj , dj , Uk+1 =
U(t+k+1)
Uk+1 =
SkUke
ρ(tk+1−tk)
1 + Uk
[
eρ(tk+1−tk) − 1
] . (8)
In this paper we will discuss only the case when doses are equispaced
∆ ≡ tj+1 − tj , (9)
and equal, thus Sk ≡ Sf . It is posible to proceed recursively from Eq. (8) to
get
Uk =
U0 (αSf )
k
1 + U0 (α− 1)
∑k−1
j=0 α
k
=
U0 (αSf )
k
1 + U0 (α− 1)
[
(αSf )k−1
αSf−1
] , (10)
were α = exp (ρ∆).
3.2. Fixed points and types of dynamics
Eq. (8) defines a discrete map whose fixed points are given by the solutions
U∞ of the equation
U =
SfUα
1 + (α− 1)U
. (11)
In the biologically relevant regime 0 ≤ U ≤ 1, Eq. (11) has two solutions:
U = 0 that is globally stable whenever Sfα < 1 and U∞ = (Sfα − 1)/(α − 1)
that has biological meaning and is stable whenever Sfα > 1 and U∞ < 1. The
condition Sfα = 1, separates two different types of dynamics: those in which
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Figure 1: Scenarios for the response of the tumor to radiotherapy depending on the values of
αSf . (a) For αSf < 1 the therapy provides a net decrease of the tumor amplitude between
doses and the maximum is reached after the treatment is completed. (b) For αSf > 1 the
tumor continues growing during the therapy.
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Figure 2: Time to malignant transformation given by Eq. (7) for different interdose spacings
∆ computed simulating Eq. (2) with doses given at equispaced times according to Eq. (5).
Parameter values are N = 30, Sf = 0.85, U0 = 0.3, U∗ = 0.5 and ρ = 0.005. A maximum
value of the time T is obtained for a value of ∆ given by Eq. (20). Below that value the
function T (∆) shows a monotonous growth and beyond that the critical U∗ is reached before
the full treatment is finished, the effective number of doses being smaller than N = 30. In this
case the improvement in time to transformation by choosing the optimal interdose spacing is
about ∆T = T (∆opt)− T (1) ≃ 660 days.
the tumor amplitude decreases through the therapy and then regrows towards
U∗ (Sfα > 1 see Fig. 1(a)), and those situations in which the tumor amplitudes
after irradiation continue growing towards U∞ (Sfα > 1 see Fig. 1(b)). In the
later case, if SfU∞ (see Fig. 1(b)) is larger than the critical amplitude U∗ the
criterion is fullfilled before the end of the therapy what is clearly a sub-optimal
situation. It is important to note that because of the radioresistance of these
tumors Sf > U∗.
3.3. Optimization problem and its solution
Thus, we wish to find, given ρ, Sf , U∗, what is the choice of ∆ providing the
maximum T given by Eq. (7) under the condition Sf > U∗. We are interested on
the range of values of ∆ for which the therapy can be completed before the tumor
amplitude reaches U∗. Choosing ∆ above that range leads to a suboptimal use
of the therapy and to smaller values of the objective function. In the range of
interest we can compute explicitly the time T in Eq. (7), that is given by the
total time of treatment plus the regrowth time, i.e.
T (∆) = N∆+
1
ρ
log
[
U∗(1− UN )
UN (1− U∗)
]
(12)
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with UN given by Eq. (10) with k = N , i.e.
UN =
U0 (αSf )
N
1 + U0 (α− 1)
[
(αSf )N−1
αSf−1
] . (13)
It is a very long but straightforward calculation to prove that
dT (∆)
d∆
> 0, (14)
what means that the optimum value for ∆ within this interval is reached exactly
on its border. Keep in mind that Eq. (12) is valid as far as U(t) ≤ U∗. Since
Uk gives the amplitude after the radiation doses, this means that the condition
for this scenario to hold is (cf. Fig. 1(b))
UN/Sf ≤ U∗ (15)
And the equality is fullfilled for the larger value of ∆ for which the therapy
is completed before the tumor reaches the critical value. Fig. 2 shows an
example computed directly from Eqs. (2) with doses given at equispaced times
according to Eq. (5) showing the existence of a single global maximum in the
time to transformation given by Eq. (7). We can compute quantitatively the
optimum interdose spacing by inserting (10) in Eq. (15) and solving for α, i.e.
solving the algebraic equation
U0
U∗
αNSN−1f = 1 + U0(α− 1)
(αSf )
N − 1
αSf − 1
(16)
Let us define x = αSf , then, we can transform Eq. (16) into
P (x) ≡
[
U0
Sf
(
1
U∗
− 1
)]
xN+1 +
[
U0
(
1−
1
U∗Sf
)]
xN+
(
U0
Sf
− 1
)
x+ (1− U0) = 0. (17)
In the range of parameters of interest (0 < U0 < U∗ < Sf < 1) it is simple to
prove that Eq. (17) has at least a root with x > 1. Moreover we can get an
estimate for the value of that root assuming N ≫ 1 and then we may retain
only the leading terms in the polinomial to get[
U0
Sf
(
1
U∗
− 1
)]
xN+1 +
[
U0
(
1−
1
U∗Sf
)]
xN ≈ 0, (18)
and from here
x ≈
1− U∗Sf
1− U∗
, (19)
what leads to the result
∆opt ≈
1
ρ
log
(
1/Sf − U∗
1− U∗
)
, (20)
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Figure 3: Comparison of the approximations for Topt obtained from the approximate equation
(20) (dotted lines) and from the exact root of the polinomial (17) (dashed lines). Parameter
values are U0 = 0.3, Sf = 0.85, U∗ = 0.5 (upper lines) and U0 = 0.3, Sf = 0.9, U∗ = 0.45
(lower lines). Shownare: (a) the values for T as a function of the proliferation ρ and (b) the
differences δT between the exact values and the predictions of Eq. (20) that are shown to be
valid to a few percent units, and thus negligible for practical purpouses.
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that is notably independent of U0 as it should be since after a large (N=30)
number of doses the dynamics is already close to the fixed point of the map
given by Eq. (11) independently of the initial value.
Eq. (20) provides a simple solution to our optimization problem that is very
accurate in the range of parameters of interest as shown in Fig. 3.
3.4. Examples
While it is clear that within the framework of our model the choice for
the spacing between doses ∆opt will lead to a longer time to the malignant
transformation than the customary choice ∆ = 1 day, it is interesting to quantify
this improvement in lifetime quantitatively. To do so we have explored the
allowed range of parameters extensively and report here a few representative
examples. In all the examples to be studied hereafter we have taken the number
of fractions to be N = 30 in agreement with usual clinical practice.
Let us first take typical values for all tumor parameters. First for the de-
tection density U0 = 0.3 that may be quite typical, next for the transformation
density U∗ = 0.5 and finally an average radiosensitivity of Sf = 0.85. The cor-
responding times to transformation following the optimal strategy versus the
customary choice of ∆ = 1 according to Eq. (12) are shown in Fig. 4(a). This
choice of parameters for average growing tumors (ρ ≈ 0.004 day−1) gives typical
times to transformation of about 5 years. In that case the improvement in time
to transformation, and correspondingly in survival using the optimal interdose
spacing, is about 2.5 years. This result is obtained with ∆opt = 0.30/ρ (cf. Eq.
(20)), what gives ∆opt ≈ 76 days for ρ = 0.004 day
−1.
Taking a more extreme set of values with a more radioresistant tumor Sf =
0.9, and a stricter criterion for transformation U∗ = 0.45 we get from Eq. (20)
∆opt = 0.184/ρ what leads to ∆opt ≈ 46 days for moderately growing tumors
(ρ = 0.004 day−1). The improvement in transformation time for this set of
parameters is shown in Fig. 4(b).
From both examples it is clear that the faster does the tumor grow, the
smaller is the gain provided by choosing the optimal interdose spacing. How-
ever, for those tumors for which the life expectancy is very bad, even small
therapeutical improvements in the range of several months are considered to be
significant.
3.5. Validation on three-dimensional spatiotemporal scenarios
Through this paper we have taken the tumor compartment dynamics be-
tween radiation doses as given by Eq. (2), instead of the more complete model
(1). There are many evidences that such approach may be valid ranging from
the results of the collective coordinate methods (Belmonte et al. 2014) or the
fact that it provides a bound for the full dynamics (Pardo et al 2014). However,
Eq. (2) might be an oversimplification of the phenomenon.
To rule out this possibility in the range of parameters of interest we have
compared the results of the predictions of Sec. 3.3 with simulations of the
full three-dimensional problem given by Eq. (1) on a cube (i.e. with Ω =
12
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Figure 4: Comparison of the time to transformation given by Eq. (12) taking the optimal
interdose time spacing ∆ (solid lines) versus the standard choice for ∆ = 1 day (dotted lines).
The difference between both curves is the estimated improvement because of the choice of the
optimal therapy (dashed lines). Shownare the results for N = 30, and two different sets of
parameter values. (a) Sf = 0.85, U0 = 0.3, U∗ = 0.5, (b) Sf = 0.9, U0 = 0.3, U∗ = 0.45. In
both cases T is a function of ρ in the range ρ ∈ [0.002, 0.01].
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[−L,L] × [−L,L] × [−L,L]). In our simulations we have used second-order
algorithms both for space and time. The results have been cross-checked using
different temporal and spatial steps and computational domain sizes to avoid
spurious discretization effects.
We have computed the dynamics of the amplitude Uh(t) = maxΩ uh(x, t), uh
being the discrete approximation to u on the lattice obtained from the three-
dimensional simulations. Given a therapeutical schedule, defined by its dose
interspacing ∆ we compute the time T that takes the amplitude to reach the
critical level for the malignant transformationU∗. Fig. 5 summarizes our results.
First, it is clear from Fig. 5 that the transformation times obtained from the
full numerical simulations of Eqs. (1) are typically larger than those obtained
from Eq. (2). This is reasonable since Eq. (2) provides the dynamics of an upper
bound for u(x, t) and thus reaches the critical amplitude well before u(x, t).
Thus the real gain in days before the malignant transformation occurs is smaller
in the framework of Eq. (1) than the one obtained from Eq. (12) (e.g. the ones
depicted in Fig. 4), but still substantial and about one year for the two sets of
parameters studied.
Both the three-dimensional data and the bounds are very close for values of
∆ close to the optimal ones. What it is more interesting is that the value for ∆
obtained from Eq. (20) predict very accurately the correct optimal values of the
optimal dose interspacing found from the full three-dimensional simulations. It
is remarkable that such a simple formula can provide the optimal values for
4. Discussion and conclusions
In this paper we have found simple equations providing the optimal dose
interspacing in radiotherapy protocols for low-grade gliomas, under the assump-
tions of equal doses per fraction and fixed spacing between doses. The predic-
tions are obtained within the framework of a simple model but have been found
to have an excellent agreement with the numerical results from fully spatio-
temporal three-dimensional mathematical models.
From the point of view of applications, the main conclusion of this paper is
that it may be possible to improve the efficacy of radiotherapy as an upfront
therapy for the management of low grade gliomas.
Specifically, the basics for improvement consists on enlarging substantially
the interval between doses from the typical choice ∆ = 1 day to larger values
obtained through Eq. (20). Thus, the results of Sec. 3 provide a theoretical
support for extremely protracted therapies for low grade gliomas. It is inter-
esting to point out that the results have a very clear biological meaning. Since
tumor regrowth is known to be faster for small tumor densities, what it is called
the accelerated repopulation phenomenon, it pays out to leave the tumor density
grow while keeping its damage under control. Our logistic growth term captures
this phenomenon to some extent.
Indeed, the effect of radiation over a population of tumor cells with so-small
fraction of proliferating cells would be minimal and thus a more effective way of
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Figure 5: Time to transformation obtained from simulations of Eq. (1) with different types of
initial data and parameter values Sf = 0.85, U0 = 0.3, U∗ = 0.5 as a function of the interdose
spacing ∆ for (a) ρ = 0.005 and (b) ρ = 0.01. The dashed lines indicate the optimal interdose
spacing given by Eq. (20) for these parameters. Circles corresponds to the results of sim-
ulations with symmetric initial data of the form u0(x, y, z) = U0sech(0.3
√
x2 + y2 + z2),
while diamonds mark the results of simulations with asymmetric initial data given by
u0(x, y, z) = 0.276 sech(0.3
√
x2 + y2 + z2) + 0.184 sech
(
0.3
√
(x− 10)2 + (y + 8)2 + z2
)
+
0.184 sech
(
0.3
√
(x+ 3)2 + (y − 1)2 + (z − 10)2
)
, that has the same initial value for U(0) =
maxx∈Ω u(x, y, z) = 0.3 as in the case of symmetric data. The solid lines correspond to the
values obtained from direct simulations of Eqs. (2), that provide upper bounds for the real
three-dimensional dynamics.
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using this therapy would be to delay fractions in time to hit new tumor subpop-
ulations once they continue through the cell cycle. These effects, not accounted
for in our model, may be incorporated by including two cell subpopulations, one
quiescent and another proliferative coupled with the first one, i.e. a compart-
ment of stem cells that in high grade glioma have a crucial role in the response
to therapies (Bao et al. 2006; Beier et al. 2008; Massey et al. 2012; Chen et al.
2012; Barrett et al. 2012; Dirks 2001)
A relevant fact is that taking ∆ above the optimal value ∆opt leads to a
sharp drop of the gain in time to the malignant transformation and even a
worse outcome than the choice ∆ = 1 (see Figs. 2 and 5). Thus, to exploit
the full power of our approach it may be necessary to have good estimates for
the tumor proliferation ρ and radiosensitivity Sf parameters. In principle it
may be possible to estimate those parameters from MRI measurements of the
response to a set of doses of radiation (Pe´rez-Garc´ıa et al 2014), thus a two-step
strategy may be designed where a first batch of radiation doses (e.g. one-two
weeks) are given intensively (∆ = 1) to treat sympthoms and characterize the
tumor parameters from the response on MRI and later the remaining set of
fractions are given optimally according to the found tumor parameters ρ, Sf .
Another possibility is to take conservative values of ∆ ≃ 20−30 day that would
lead to improvements, though non-optimal, for most tumors except for those
very aggressive (large ρ) and then in case of radiological confirmation of tumor
control after some period of time (e.g. one year) enlarge the interval between
fractions.
In this paper we have tried only to make a first approach to the problem
through a proof of concept of the basic idea. Further gains may be possible by
solving the full optimization problem were the number of doses N , treatment
times tj and individual doses dj are variables to be choosen to maximize the
malignant transformation time (7). While the mathematical problem is inter-
esting and we intend to address it in the future, complex strategies depending
too much on the values system parameters might be difficult or even impossi-
ble to validate and implement due to parameter uncertainty and may have no
impact on the clinical management of these tumors. Thus we have opted for
a simpler approach easier to validate in animal models and to translate into
current clinical practice.
Can the extreme protraction concept be exported to other therapies such
as chemotherapy for low grade gliomas? Currently, the most used chemothera-
peutical scheme consists of a week treatment (an oral dose per day) per month,
being repeated for several cycles (months). Although this scheme is already
more extended in time, there might be benefit either in enlarging the interval
between cycles or in extending the interval between doses within a given cycle.
Since side effects in chemotherapy are systemic instead of mostly local for RT,
different models and/or restrictions are to be used for that problem, that will
be considered in the future.
We hope our results will motivate research on animal models of low-grade
gliomas and a further translation to the clinical practice if sucessful, on the
benefit of patients of this lethal disease.
16
Acknowledgements
This work has been partially supported by the Ministerio de Economı´a y
Competitividad (Spain), under grant MTM2012-31073. I wish to acknowledge
Alicia Mart´ınez-Gonza´lez, Juan Belmonte (Universidad de Castilla-La Mancha),
Juan M. Sepu´lveda (Hospital 12 de Octubre), Luis Pe´rez-Romasanta (Hospital
Universitario de Salamanca), Pilar Sa´nchez (Instituto de Salud Carlos III) for
discussions.
17
References
Alvord EC Jr, Swanson KR, 2007. Using mathematical modeling to predict
survival of low-grade gliomas. Ann. Neurol. 61, 496.
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW,
Bigner DD, Rich JN, 2006. Glioma stem cells promote radioresistance by
preferential activation of the DNA damage response. Nature 444, 756-760.
Barazzuol L, Burnet NG, Jena R, Jones B, Jefferies SJ & Kirkby NF,
2010. A mathematical model of brain tumour response to radiotherapy and
chemotherapy considering radiobiological aspects. J. Theor. Biol., 262, 553-
565.
Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC,
Nam HS, Benezra R., 2012. Self-renewal does not predict tumor growth po-
tential in mouse models of high-grade glioma. Cancer Cell, 21, 11-24.
Beier D, Ro¨hrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P,
Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wis-
chhusen J, Reifenberger G, Hau P, Beier CP, 2008. Cancer Res. 68, 5706-5715.
Belmonte J, Calvo GF & Pe´rez-Garc´ıa VM, 2014. Effective particle methods
for Fisher-Kolmogorov equations: Theory and applications to brain tumor
dynamics, Commun Nonlinear Sci Numer Simulat, 19, 3267-3283.
Bondiau PY, Frenay M & Ayache N, 2008. Biocomputing: numerical simulation
of glioblastoma growth using diffusion tensor imaging. Phys. Med. Biol. 53,
879-893.
Bondiau PY, Konukoglu E, Clatz O, Delingette H, Frenay M, Paquis P, 2010.
Biocomputing: numerical simulation of glioblastoma growth and comparison
with conventional irradiation margins. Phys. Med. 27, 103-108.
Chao ST & Suh JH, 2006. When should radiotherapy for low-grade glioma be
given?immediately after surgery or at the time of progression? Nature Clinical
Practice 3, 136-137.
Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF, 2012. A
restricted cell population propagates glioblastoma growth after chemotherapy,
Nature 48, 522-526.
Clatz O, Sermesant M, Bondiau PY, Delingette H, Warfield SK, Malandain G,
Ayache N., 2005. Realistic simulation of the 3-D growth of brain tumors in
MR images coupling diffusion with biomechanical deformation, IEEE Trans
Med Imaging, 24, 1334-1346.
Deroulers C, Aubert M, Badoual M, Grammaticos B, 2009. Modeling tumor
cell migration: From microscopic to macroscopic models. Phys. Rev. E, 79,
031917.
18
Dirks PB, 2001. Glioma migration: clues from the biology of neural progenitor
cells and embryonic CNS cell migration. J. Neurooncol. 53, 203-212.
Eikenberry SE & Kuang Y, 2009. Virtual glioblastoma: growth, migration and
treatment in a three-dimensional mathematical model. Cell Prolif. 42, 511-
528.
Fedotov S, Iomin A, & Ryashko L, 2011. Non-Markovian models for migration-
proliferation dichotomy of cancer cells: Anomalous switching and spreading
rate. Phys. Rev. E 84, 061131
Frieboes HB, Bearer E & Cristini V, 2007. Computer simulation of glioma
growth and morphology. Neuroimage 37, S59-S70.
Galochkina T, Bratus A & Pe´rez-Garc´ıa VM, 2014. Optimal radiotherapy pro-
tocols for low-grade gliomas: Insights from a mathematical model (preprint).
Garcia DM, Fulling KH, Marks JE, 1985. The value of radiation therapy in
addition to surgery for astrocytomas of the adult cerebrum. Cancer 55, 919-
927.
Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, Varlet P, Capelle
L, Taillandier L, Bauchet L, Duffau H & Badoual M, 2012. Improving the
time-machine: estimating date of birth of grade II gliomas. Cell Proliferation,
45, 76-90.
Grier JT & Batchelor T, 2006. Low-Grade Gliomas in Adults. The Oncologist
11, 681-693.
Gu S, Chakraborty G, Champley K, Alessio AM, Claridge J, Rockne R, Muzi
M, Krohn KA, Spence AM, Alvord EC Jr, Anderson AR, Kinahan PE, Swan-
son KR, 2012. Applying a patient-specific bio-mathematical model of glioma
growth to develop virtual [18F]-FMISO-PET images. Math. Med. Biol. 29,
31-48.
Harpold HL, Alvord EC Jr, Swanson KR, 2007. The evolution of mathematical
modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 66,
1-9.
Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A, 2012. ’Go or grow’:
the key to the emergence of invasion in tumour progression? Math. Med. Biol.
29, 49-65.
Higuchi Y, Iwadate Y & Yamaura A, 2004. Treatment of low-grade oligoden-
droglial tumors without radiotherapy. Neurology, 63, 2384-2386.
Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G, Solheim O,
2012. Comparison of a strategy favoring early surgical resection vs a strategy
favoring watchful waiting in low-grade gliomas. JAMA 308, 1881-1888.
19
Jbabdi S, Mandonnet E, Duffau H, Capelle L, Swanson KR, Pelegrini-Issac M,
Guillevin R & Benali H, 2005. Simulation of Anisotropic Growth of Low-Grade
Gliomas Using Diffusion Tensor Imaging. Magnetic Resonance in Medicine 54,
616-624.
Konukoglu E, Clatz O, Bondiau PY, Delingette H & Ayache N, 2010. Extrapo-
lating glioma invasion margin in brain magnetic resonance images: suggesting
new irradiation margins. Med. Image Anal. 14, 111-125.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Schei-
thauer BW & Kleihues P, 2007. World health organization classification of
tumours of the central nervous system, 4th ed., Renouf Publishing Co. Ltd.,
Geneva. pp. 33-46.
Lowengrub JS, Frieboes HB, Jin F, Chuang YL, Li X, Macklin P, Wise SM,
Cristini V, 2010. Nonlinear modelling of cancer: bridging the gap between
cells and tumours. Nonlinearity, 23, R1-R91.
Mandonnet M, Taillandier L, Capelle L, Fontaine D, Peyre M, Ducray F, Duf-
fau H, Mandonnet E, 2012. Quantitative Morphological MRI Follow-up of
Low-grade glioma: A Plead for Systematic Measurement of Growth Rates,
Neurosurgery 71, 729-740.
Mart´ınez-Gonza´lez A, Calvo GF, Pe´rez-Romansanta LA, Pe´rez-Garc´ıa VM,
2012. Hypoxic Cell Waves around Necrotic Cores in Glioblastoma: A
Biomathematical Model and its Therapeutic Implications. Bull Math Biol
74, 2875-2896.
Mart´ınez-Gonza´lez A, Dura´n-Pardo M, Calvo GF, Alca´ın FJ, Pe´rez-Romasanta
LA, Pe´rez-Garc´ıa VM, 2014. Combined therapies of antithrombotics and an-
tioxidants delay in silico brain tumors progression. Mathematical Medicine
and Biology 10.1093/imammb/dqu002
Massey SC, Assanah MC, Lopez KA, Canoll P, Swanson KR, 2012. Glial pro-
genitor cell recruitment drives aggressive glioma growth: mathematical and
experimental modelling. J R Soc Interface, 9, 1757-1766.
Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascaren-
has F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van
Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke
M, 1996. A randomized trial on dose-response in radiation therapy of low-
grade cerebral glioma: European Organization for Research and Treatment
of Cancer Study (EORTC) Study 22844. International Journal of Radiation,
Oncology, Biology & Physics, 36, 549-556.
Leder K, Pitter K, LaPlant Q, Hambardzumyan D, Ross BD, Chan TA, Holland
EC, Michor F, 2014. Mathematical Modeling of PDGF-Driven Glioblastoma
Reveals Optimized Radiation Dosing Schedules, Cell 156, 603-616.
20
Murray JD (2007) Mathematical Biology: I. An Introduction, Springer.
Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M, 2004.
Radiotherapy for high-grade gliomas. Does altered fractionation improve the
outcome? Strahlenther Onkol. 180, 401-407.
Pallud J, Taillandier L, Capelle L, Fontaine D, Peyre M, Ducray F, Duffau
H, Mandonnet E., 2012. Quantitative Morphological MRI Follow-up of Low-
grade Glioma: A Plead for Systematic Measurement of Growth Rates. Neu-
rosurgery, 71, 729-740.
Pallud J, Llitjos JF, Dhermain F, Varlet P, Dezamis E, Devaux B, Souillard-
Scemama R, Sanai N, Koziak M, Page P, Schlienger M, Daumas-Duport C,
Meder JF, Oppenheim C & Roux FX, 2012. Dynamic imaging response fol-
lowing radiation therapy predicts long-term outcomes for diffuse low-grade
gliomas. Neuro-Oncology 14, 496-505.
Pardo R, & Mart´ınez-Gonza´lez A, Pe´rez-Garc´ıa, VM, 2014. Waves of cells with
an unstable phenotype accelerate progression in high-grade gliomas. J. Math.
Biol. (submitted) arxiv.org/abs/1405.0369
Pe´rez-Garc´ıa VM, Calvo GF, Belmonte-Beitia J, Diego D & Pe´rez-Romasanta
L, 2011. Bright solitary waves in malignant gliomas. Phys. Rev. E 84, 021921.
Pe´rez-Garc´ıa VM, Bogdanska M, Mart´ınez-Gonza´lez A, Belmonte-Beitia J,
Schucht P, Pe´rez-Romasanta L, 2014. Delay effects in the response of
low grade gliomas to radiotherapy: A mathematical model and its ther-
apeutical implications. Mathematical Medicine and Biology (to appear)
http://arxiv.org/abs/1401.2603
Pe´rez-Romasanta LA, Belmonte-Beitia J, Mart´ınez-Gonza´lez A, Calvo GF,
Pe´rez-Garc´ıa VM, 2013. Mathematical model predicts response to radiother-
apy of grade II gliomas, Reports of Practical Oncology and Radiotherapy, 18,
S63.
Pignatti F, van den Bent M, Curran et al., 2002. Prognostic factors for survival
in adult patients with cerebral low-grade glioma. J Clin Oncol, 20, 2076-2084.
Poon E, Harris AL, Ashcroft M, 2009. Targeting the hypoxia-inducible factor
(HIF) pathway in cancer, Expert Rev Mol Med 11, e26.
Pouratian N & Schiff D, 2010. Management of low-grade glioma. Curr Neurol
Neurosci Rep, 10, 224-31.
Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B,
Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY,
Honnorat J, Grenier E, Ducray F, 2012. A tumor growth inhibition model
for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer
Res. 15, 5071-5080.
21
Rockne R, Hendrickson K, Lai A, Cloughesy T, Alvord EC Jr & Swanson KR,
2010. Predicting the efficacy of radiotherapy in individual glioblastoma pa-
tients in vivo: a mathematical modeling approach. Phys. Med. Biol. 55, 3271-
3285.
Roniotis A, Marias K, Sakkalis V, Zervakis M, 2010. Diffusive modelling of
glioma evolution: A review, J. Biomedical Science and Engineering 3, 501-
508.
Ruiz J & Lesser GJ, 2009. Low-Grade Gliomas. Current Treatment Options in
Oncology, 10, 231-242.
Semenza GL, Targeting HIF-1 for cancer therapy, 2003. Nature Rev Cancer 3,
721-732.
Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Fre´nay M, Grisold
W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T,
Smits A, Stupp R, Wick W, 2010. Guidelines on management of low-grade
gliomas: report of an EFNS-EANO Task Force. Eur J Neurol, 17, 1124-1133.
Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan
T, Vandenberg S, McDermott MW & Berger MS, 2008. Role of extent of
resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin.
Oncol., 26, 1338-1345.
Stamatakos GS, Antipas VP, Uzunoglu NK, 2006. A Spatiotemporal Patient In-
dividualized Simulation Model of Solid Tumor Response to Chemotherapy in
Vivo: The Paradigm of Glioblastoma Multiforme Treated by Temozolomide.
IEEE Trans. Biomed. Eng. 53, 1467-1477.
Stamatakos GS, Antipas VP, Uzunoglu NK, 2006. Simulating chemotherapeutic
schemes in the individualized treatment context: The paradigm of glioblas-
toma multiforme treated by temozolomide in vivo. Comp. in Biol. and Med,
36, 1216-1234.
Swanson KR, Bridge C, Murray JD, Alvord EC Jr, 2003. Virtual and real brain
tumors: using mathematical modeling to quantify glioma growth and inva-
sion. J Neurol Sci. 216, 1-10.
Swanson KR, Rostomily RC & Alvord EC Jr, 2008. A mathematical mod-
elling tool for predicting survival of individual patients following resection of
glioblastoma: a proof of principle. Br. J. Cancer, 98, 113-119.
Swanson KR, Rockne RC, Claridge J, Chaplain MA, Alvord EC Jr, Anderson
AR, 2011. Quantifying the role of angiogenesis in malignant progression of
gliomas: in silico modeling integrates imaging and histology. Cancer Res 7,
7366-7375 .
Tanaka ML, Debinski W, Puri IK, 2009. Hybrid Mathematical model of glioma
progression, Cell. Prolif., 42, 637-646.
22
Van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-
Xuan K, Malmstro¨m PO, Collette L, Pie´rart M, Mirimanoff R & Karim AB,
2005. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised
trial, Lancet, 366, 985-990.
Van der Kogel, A., & Joiner, M., Basic clinical radiobiology, Oxford University
Press, 2009.
Wang CH, Rockhill JK, Mrugala M, Peacock DL, Lai A, Jusenius K, Wardlaw
JM, Cloughesy T, Spence AM, Rockne R, Alvord EC Jr & Swanson KR, 2009.
Prognostic significance of growth kinetics in newly diagnosed glioblastomas
revealed by combining serial imaging with a novel biomathematical model.
Cancer Res., 69, 9133-9140.
Wigg D, 2001. Applied radiobiology and bioeffect planning, Medical Physics Pub
Corp.
23
